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MoCAObjective: To evaluate the cognitive status in patients with bronchial asthma and chronic obstructive pul-
monary disease (COPD).
Methods: 40 patients with bronchial asthma, 40 patients with COPD and 20 healthy subjects (control)
were included in the study. Comparison was done between the three groups in both Montreal
Cognitive Assessment (MoCA) test and P300 latency. Also, correlation between these scores and patient
characteristic parameters were evaluated.
Results: There was a significant prolongation in P300 latency (P < 0.04) and reduced MoCA scores in COPD
group compared to asthma group (P < 0.002). 34/40 COPD patients had prolongation of P300 latency and
reduced MoCA scores. However, 20/40 asthma patients had prolongation of P300 latency and 24/40
asthma patients had reduced MoCA scores. P300 latency correlated significantly with age (r = 0.423,
P < 0.007), duration of disease(r = 0.622, P < 0.0001) PaO2 (r = 0.490, P < 0.001), SaO2 (r = 0.496,
P < 0.003) and degree of the disease (FEV1/FVC) (r = 0.353, P < 0.026) in COPD group. MoCA score was
significantly correlated with WBC (r = 0.45) in COPD group and with BMI (r = 0.236, P < 0.05) in asthma
group. There was no correlation between P300 latency and patients’ characteristics in asthma group
(P > 0.05).
Conclusions: COPD significantly decreased the cognitive status compared to bronchial asthma. Longer
latency of P300 appears to be an expected sequel of COPD. MoCA abnormalities were comparable to
P300 abnormalities in COPD and asthma patients.
 2016 Egyptian Society of Ear, Nose, Throat and Allied Sciences. Production and hosting by Elsevier B.V.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).1. Introduction
Chronic diseases of respiratory system become a serious public
health problem all over the world. The most prevalent are obstruc-
tive diseases (asthma and COPD). The common denominator of
both diseases is chronic inflammation leading to airway obstruc-
tion. The main differences are the distinct features of inflammation
and reversibility of obstruction as it is reversible in asthma, while it
progressively worsens and is irreversible in COPD. In asthma, the
inflammatory infiltrate is predominantly composed of eosinophils,
mast cells and CD4 T (Th2) lymphocytes, while in COPD it is mainly
formed by neutrophils, macrophages and CD8 T (Th1) lympho-cytes.1. Both diseases have been found to be co morbid with cogni-
tive disorders.2,3 A mechanism proposed for the cognitive
impairment in COPD patients is the neuronal damage mediated
by hypoxia as a result of the pulmonary disease or the co morbidi-
ties that adversely affect the brain, such as vascular disease and
smoking.4 Mild cognitive impairment(MCI) is defined as a clinical
condition characterized by the decline of cognitive function greater
than expected for a certain age and educational level of the individ-
ual but not severe enough to interfere with their daily activities.5
The Montreal Cognitive Assessment test is an efficient instrument
to use for screening, diagnosis and tracking of MCI. It assesses dif-
ferent cognitive domains, has good psychometric properties and
has become a widely used screening instrument for MCI.6 Also,
P300 is an electrophysiological test which is a valuable tool for
assessing cognitive function.7 The changes in P300 amplitude
reflect the degree and quality of information processing. P300
latency is related with cognition ability, attention, and the capacityCOPD).
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which compare the cognitive function in asthma and COPD
patients. We adopted both P300 and MoCA test to assess cognitive
functions in these patients simultaneously to study their relative
relevance in clinical setup in addition to measure the correlation
between these scores and patient characteristic parameters.2. Materials and methods
2.1. Study design
It is cross-section, observational study. Our patients were
selected from the patients admitted in the Department of Chest
Medicine, Sohag University Hospitals, while the control group
was selected from healthy volunteers. All cognitive assessment
tests were performed in audiology unit, Sohag university Hospitals.
The Ethics Committee of Sohag faculty of Medicine reviewed and
approved the protocol, and all patients signed informed consent
after the nature of the study had been fully explained prior to their
participation.
2.2. Subjects
Our participants were divided into 3 groups, based on spirome-
try with reversibility test and physical examination, patients with
asthma, COPD and control group. In asthma group; they were 40
patients, all of them selected according to the GINA criteria for
asthma – typical symptoms, typical interview, variable and rever-
sible airway obstruction on spirometry tests – recently or docu-
mented in the past and were in a stable period of the disease
(based on medical history and physical examination). Asthma
patients only inhaled Steroid which have no systemic effect. 40
COPD patients were selected according to the Gold criteria for
COPD. All patients in this group had typical interview (exertional
dyspnea, progressive, chronic, productive cough), FEV1/FVC < 40
and >80 years, illiteracy, alcoholism, obesity, long term oxygen
therapy, severe cardiovascular co-morbidities, cancer, uncon-
trolled diabetes, major cognitive impairment, history of head
injury or brain tumor, dementia, or epilepsy. COPD patients are
not using steroid. All subjects underwent the following: 1-An
extensive physical examination. 2-Hearing assessment through;
otological examination, two cannel pure tone audiometer, Madsen
model, 922 and Immittancemetry, Amplaid model 775. The oxygen
pressure (PaO2), oxygen saturation (SaO2) and carbon dioxide
pressure (PaCO2) were analyzed in radial artery blood samples.
The respiratory function tests were performed using a spirometry
device (Superspiro, Micromedical Limited, Rochester, England).
Forced expiratory volume (FEV1), forced vital capacity (FVC),
FEV1/FVC parameters were measured.
2.3. Assessment of Cognitive Ability
Montreal Cognitive Assessment: it is a 30 point test that takes
10 to 15 min to be completed. It assesses several cognitive
domains. A score below 26 points indicates mild cognitive impair-
ment. It assesses visuospatial abilities using a clock drawing task (3
points), and a three-dimensional cube copy (1 point). Multiple
aspects of executive functions are assessed using a trail making
task (1 point), a phonemic fluency task (1 point), and a two item
verbal abstraction task (2 points). MoCA test was validated to be
used as screener as the author used the Montreal Cognitive Assess-
ment, but not the Mini-Mental State Examination, ahichhas ade-
quate psychometric properties as a screening instrument for the
detection of mild cognitive impairment. Language is assessed using
a three item confrontation naming task with familiar animals (3Please cite this article in press as: Mourad S., et al. Cognitive profile in patients
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points). Short term memory is evaluated with a task that involves
two learning trials of five nouns and delayed recall after approxi-
mately 5 min (5 points). Attention, concentration and working
memory are evaluated using a sustained attentions task (target
detection using tapping, (1 point), digits forward and backward
(1 point each) and a serial subtraction task (3 points). At the end
of the test, orientation and place is assessed (6 points). In all
patients, the P300 ERP recordings were taken before breakfast (at
8:30 AM) after an optimal overnight sleep. The stimulus was tonal
stimuli as the speech stimuli is not present in our instrument. The
‘odd-ball paradigm’ was applied to all subjects. In this paradigm,
standard (1000 Hz) and target (4000 Hz) auditory stimuli with
duration of 1000 ms were presented to the subject binaurally over
headphones. The deviant tone was designated as target and was
counted by the patient. The target tone occurred regularly with a
0.20 probability. The rise and fall time of each tone was 5 ms.
Recording conditions: Electroencephalogram (EEG) activity was
recorded at the frontal (Fz), central (Cz) and parietal (P3 and P4)
electrode sites of the 10/20 international system using Ag/AgCl
electrodes, fixed with electrode paste and tape, with an impedance
of 5 kOm or less. The reference electrode was attached to the right
mastoid and the ground electrode was attached to the left mastoid.
The signals from the electrodes were amplified and band-passed
between 0.3 and 100 Hz. EEG was digitized at 1000 Hz with a
1024 ms pre-stimulus baseline. The P300 targeted/frequent stimu-
lus latency expressed numerically with reference value
300 ± 10 ms. The P300 amplitude was not calculated as it is highly
variable in our instrument.
2.4. Statistical analysis
Data was collected and analyzed using SPSS v.17.0 (SPSS Inc,
Chicago, IL, USA) and is presented as mean ± standard deviations.
To assess the significance of the differences between groups, the
ANOVA along with Bonferroni post-hoc.was used. The strength of
correlations between variables was assessed using Spearman’s cor-
relation coefficient and its statistical significance with t-
distribution test. A P value of <0.05 was considered the threshold
for statistical significance.3. Results
3.1. Demographic characteristics in the control
Asthma and COPD Groups Demographic features of asthma,
COPD and control groups are shown in Table 1. This study included
100 participants, 46 women and 54 men. They were 80 patients
with obstructive lung diseases (40 adult onset asthma and 40
COPD patients), in addition to 20 healthy subjects as a control
group. The average ages in asthma, COPD and control groups were
44.5 ± 13.5, 60.85 ± 19.8 and 53.5 ± 14.8 years respectively.
3.2. MCI Frequency
MoCA mean score in asthma, COPD and control groups were
20.4 ± 4.65, 16.4 ± 6.3 and 28.4 ± 5.85 (Fig. 1) and prevalence of
MCI in these groups were 60%, 85% and 15% respectively (Table 2).
P300 latency in asthma, COPD and control groups were
312 ± 28.99, 324.25 ± 21.91 and 305 ± 10.27 (Fig. 2) and prevalence
of MCI were 50%, 85% and 10% respectively (Table 2). The MoCA
score was significantly lower in asthma and COPD groups
(P < 0.0001) compared with the score in the control group. Further-
more, the MoCA score declined significantly in the COPD compared
with that in the bronchial asthma (P < 0.001). Mean scores on thewith bronchial asthma and chronic obstructive pulmonary disease (COPD).
16.06.004
Table 1
Comparison of patients’ parameters between studied groups.
Parameter Asthma (A) N = 40 COPD (B) N = 40 Controls (C) N = 20 P value A vs. C P value A vs. B
Age 44.5 (13.5) 60 (19.85) 53.5 (14.8) 0.0001 0.0001
Sex
Females 28 (70.00%) 10 (25%) 8 (40.00%) <0.0001 <0.0001
Males 12 (30%) 30 (75%) 12 (60.00%)
BMI 22.77 ± 4.18 23.22 ± 3.97 22.54 ± 3.18 0.79 0.62
Duration of the disease 16.2 ± 9.54 13.2 ± 5.62 – 0.32
WBCs 10.67 ± 3.92 9.34 ± 3.53 10.52 ± 4.53 0.28 0.11
CRP 6.1 (2) 6 (4) 6 (2) 0.89 0.80
PH 7.42 ± 0.03 7.38 ± 0.07 7.40 ± 0.05 0.003 0.0007
PaCO2 32.78 ± 4.22 45.15 ± 10.96 38.3 ± 4.19 <0.0001 <0.0001
PaO2 83.05 ± 15.29 64.29 ± 15.16 88.14 ± 8.01 <0.0001 <0.0001
SaO2 93.75 ± 3.10 83.35 ± 14.34 94.15 ± 3.16 <0.0001 <0.0001
FEV1 44.85 ± 17.89 47.35 ± 13.73 85.3 ± 2.87 <0.0001 0.49
FVC 63 ± 14.84 55.4 ± 16.03 83.4 ± 9.03 <0.0001 0.03
FEV1/Fvc 65.15 ± 13.02 61.25 ± 17.51 86.05 ± 4.36 <0.0001 0.26
Results are presented as mean ± standard deviation. P values were calculated with unpaired t-student and ANOVA tests. Column 5 is the correlation between A, B, C.
CRP – C-reactive protein, BMI – body mass index, WBC – White blood cell, FVC – Force vital capacity, FEV1 – Forced expiratory volume.
Fig. 1. MoCAmean scores in control, COPD and bronchial asthma. MCI Frequency
MoCAmean score in control, COPD and asthmagroups were 20.4 ± 4.65, 16.4 ± 6.3
and 28.4 ± 5.85.
S. Mourad et al. / Egyptian Journal of Ear, Nose, Throat and Allied Sciences xxx (2016) xxx–xxx 3MoCA scale corresponding to moderate to severe cognitive impair-
ment in COPD patients, while scores in bronchial asthma corre-
sponding to the result of mild cognitive impairment. It was
found that the latency of P300 was prolonged in COPD group com-
pared to asthma group (P < 0.04).3.3. Correlation between cognitive function and clinical parameters
There was a significant correlation between MoCA score and
WBC (r = 0.450, P < 0.003), in patient with COPD group and with
BMI(r = 0.427, P < 0.006) in asthma group (Table 3). P300 latency
was correlated significantly with age (r = 0.423, P < 0.007), sex
(r = 0.304, P < 0.059), PaO2 (r = 0.490, P < 0.001), SaO2
(r = 0.496, P < 0.003), FEV1/FVC (r = 0.353, P < 0.026) values.
Interestingly, there was a significant correlation between P300
latency, and duration of the disease(r = 0.622, P < 0.0001). How-
ever, there was no statistical significant correlation betweenTable 2
Percentage of MCI and P300 in COPD and asthma subjects.
Items Asthma
Montreal cognitive assessment 20.4 ± 4.65
Normal 16 (40.00%)
Abnormal 24 (60.00%)
P300 312 ± 28.99
Normal 20 (50.00%)
Abnormal 20 (50.00%)
Results of MoCA in control group was 15% as three case with cognitive impaired was
cognition.
Please cite this article in press as: Mourad S., et al. Cognitive profile in patients
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for all) (see Table 4).4. Discussion
The cognitive impairment is a significant concern for elderly
because it decreases the quality of life and, in advance stages, it
might cause functional disabilities. These findings are of special
clinical relevance because cognitive dysfunctions among asthma
and COPD patients remain often undetected and untreated in daily
clinical practice. This may be because the screening tools for cogni-
tive dysfunctions are not routinely employed and that on the other
hand, patients often tend to deny that they are suffering from these
conditions due to the stigma attached to them. To our knowledge
this is the first study which uses MoCA test and P300 simultane-
ously to assess the cognition in patients with asthma and COPD.
Comparing MOCA test to MiniMental State Examination test
(MMSE) in detecting the earliest stages of impairment. Dong
et al. (2012) and Villeneuve et al. (2012) compared these tests
and concluded that MoCA is superior to MMSE in detection of
patients with cognitive impairment.9,10 In the present study P300
and MoCA were used simultaneously to assess cognitive functions;
the utility of each one of them for assessment of cognitive func-
tions has been established in prior studies. Al Tahan et al. (2010)
found that MMSE alone is an insensitive tool and they recom-
mended P300 latency to assess cognitive dysfunctions.11 For these
reasons, we used P300 in addition to MoCA for cognitive assess-
ment. In our study MoCA mean score in asthma, COPD and control
groups were 20.4 ± 4.65, 16.4 ± 6.3 and 28.4 ± 5.85 and prevalence
of MCI in these groups were 60%, 85% and 15% respectively. P300
latency in asthma, COPD and control groups were 312 ± 28.99,
324.25 ± 21.91 and 305 ± 10.27 and prevalence of MCI were 50%,
85% and 10% respectively. The mean MoCA score in COPD patient’sCOPD Control P-value
16.4 ± 6.30 28.4 ± 5.85 0.002
6 (15.00 %) 17 (85%) <0.01
34 (85.00%) 3 (15%)
324.25 ± 21.91 305.13 ± 10.27 0.04
6 (15.00%) 18 (90%) 0.001
34 (85.00%) 2 (10%)
removed and the test was repeated with 3 other healthy volunteers with normal
with bronchial asthma and chronic obstructive pulmonary disease (COPD).
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Fig. 2. P300 Latency in control, COPD and bronchial asthma. P300 latency in
control, COPD and asthma groups were 312 ± 28.99, 324.25 ± 21.91 and
305 ± 10.27.
Table 3
Correlation between MoCA score and clinical parameters.
Test parameter Asthma COPD
r P r P
Age 0.083 0.609 0.274 0.087
Sex 0.193 0.347 0.201 0.214
Duration of disease 0.04 0.79 0.15 0.35
BMI 0.427 0.006 0.14 0.40
CRP 0.01 0.95 0.09 0.58
WBC 0.03 0.86 0.45 0.003
FEV1 0.27 0.09 0.16 0.31
FVC 0.141 0.387 0.264 0.099
FEV1/FVC 0.250 0.120 0.281 0.079
SaO2 0.065 0.692 0.074 0.651
PaO2 0.14 0.39 0.07 0.66
PaCO2 0.15 0.34 0.08 0.64
Table 4
Correlation between P300latency and clinical parameters.
Test parameter Asthma COPD
r P r P
Age 0.091 0.576 0.423 0.007
Sex 0.057 0.726 0.304 0.059
Duration of disease 0.083 0.691 0.622 0.0001
BMI 0.032 0.887 0.290 0.070
CRP 0.180 0.265 0.005 0.974
WBC 0.038 0.818 0.045 0.741
FEV1 0.192 0.236 0.238 0.139
FVC 0.020 0.901 0.093 0.568
FEV1/FVC 0.076 0.0639 0.353 0.026
SaO2 0.048 0.769 0.496 0.003
PaO2 0.037 0.822 0.490 0.001
PaCO2 0.283 0.077 0.178 0.272
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impairment,12 while scores in bronchial asthma patients scale
was 20.4 ± 4.65, corresponding to the result of mild cognitive
impairment. These results are in agreement with the results of
Preda et al. (2013) for MoCA test.13
In our study, P300 abnormalities were comparable to MoCA
abnormalities in COPD but less in asthma. The MoCA has been
found to be superior to the P300 in detecting MCI in asthma pop-
ulations. Hence, compared with the P300, the current study
showed that the MoCA is an appropriate and validated brief
screening test for detecting MCI in patients with asthma and COPD.
This has the potential to be clinically important, to detect hidden
cognitive problems in asthma and COPD patients. Nevertheless,
our findings are largely in agreement with the published data ofPlease cite this article in press as: Mourad S., et al. Cognitive profile in patients
Egypt J Ear Nose Throat Allied Sci (2016), http://dx.doi.org/10.1016/j.ejenta.20other studies. Cognitive dysfunction is highly prevalent in both
COPD and asthma patients.2,3 The first study providing information
on cognitive dysfunctions in asthma patients was conducted in
1981 by Schraa et al. they revealed that a majority of the asthmat-
ics manifested definite signs of memory impairment when they
were asked to recall.14 In the largest sample cross sectional study
so far asthma was associated with 78% increased risk of cognitive
impairment when controlling for demographic characteristics,
self-rated health status, inhaled corticosteroid use and FEV1/
FVC.15 The underlying mechanisms of cognitive impairments in
COPD remain controversial issue. Hypoxemia, hypercapnia, or vas-
cular co morbidities have been proposed as possible causes of brain
alterations in patients with COPD.16 Guo et al. (2013) reported that
chronic asthma impairs cognitive function and synaptic plasticity,
down-regulation of c-fos, Arc and neurogenesis induced by inter-
mittent hypoxia during chronic asthma might contribute to learn-
ing and memory dysfunctions.17 In our study, there is a significant
correlation between MoCA test and WBC count in COPD patients.
Patients who had a high level of WBC had a lower MoCA score. It
is well known that the most important risk factor that leads to
COPD is smoking. All our COPD patients in this study were smok-
ers, so we assume that the inflammatory cytokines released by
neutrophils over years because of smoking might have led to
synaptic alteration and so, the destruction on existing neurons,
led to a decrease of cognitive function.18 MoCA is only correlated
with BMI(r = 0.427, P < 0.006) in asthma group. The scores of
MoCA progressively decreased across the spectrum from mild
overweight to obese groups in addition19 P300 latency was signif-
icantly prolonged in COPD groups compared to asthma group. This
result may be related to one or any number of the factors such as
oxygen saturation, PaO2, PaCO2 and FEV1. In fact, in this study,
P300 latency correlated significantly with PaO2, SaO2, FEV1/FVC
values and age. Interestingly, there was a significant correlation
between P300 latency, and duration of the disease(r = 0.622,
P < 0.0001). Our results were compatible with other studies. A pos-
itive correlation was found between P300 latency and age
(r = 0.423, P < 0.007). It is well known that cognitive skills decline
with age.20. It has been proposed that the mechanism underlying
the positive relationship between age and cognitive functioning
is cerebral oxygenation.21. P300 latency negatively correlated with
FEV1/FVC (r = 0.353, P < 0.026). Reeves et al. (1999)22 reported
that auditory P300 latency was negatively correlated with pul-
monary function in COPD patients. We found a negative correlation
between P300 latency and both PaO2 and SaO2 [PaO2 (r = 0.490,
P < 0.001), SaO2 (r = 0.496, P < 0.003)]. Grant et al. 198223 found
an inverse correlation between neurologic decline and rest O2 sat-
uration. There are some studies that found a significant correlation
between low PaO2 and measures of cognitive performance.21,24 We
did not found any statistical significant correlation between P300
abnormalities and asthma patients’ characteristics (P > 0.05 for
all). The identification of existence of subclinical cognitive dysfunc-
tions in asthma and COPD patients has significant impact over the
disease as patients with untreated cognitive difficulties may dete-
riorate with faster rates and have worse health outcomes than cog-
nitively intact patients.24 Moreover, the cognitive dysfunctions are
also recognized to be associated with increased mortality and dis-
ability. The influence of COPD on cognitive performance is partially
reversible using oxygen therapy and physical activity, which is
often not, appreciated enough.5. Conclusion
Both bronchial asthma and COPD patients are at a great risk of
cognitive disorders so, self administering MoCA test, Consultation
andmedical therapies are necessary for screening of these patients.with bronchial asthma and chronic obstructive pulmonary disease (COPD).
16.06.004
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